Efficacy and Safety of an LVEF-Guided Mavacamten Dose Up-Titration Strategy in Chinese Patients With Symptomatic Obstructive Hypertrophic Cardiomyopathy
A phase 4 trial registered on ClinicalTrials.gov. The registry status is not yet recruiting. It plans to enroll 115 participants.
Also called NCT07807384
- Study
- In this atlas
Overview
- Design
- Interventional study; allocation not applicable; no masking; primary purpose treatment
- Phase
- Phase 4
- Enrolled
- 115 participants
- Registry
-
NCT07807384
-
- Planned start
- (anticipated)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- Not reported
- Registry status
- Not yet recruiting
Technical summary
Registry record NCT07807384. Allocation not applicable; no masking; primary purpose treatment. Start 2026-11 (anticipated); primary completion 2029-09 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Efficacy and Safety of an LVEF-Guided Mavacamten Dose Up-Titration Strategy in Chinese Patients With Symptomatic Obstructive Hypertrophic Cardiomyopathy
- Condition
- Obstructive Hypertrophic Cardiomyopathy (oHCM)
- Intervention (Drug)
- Mavacamten
- Lead sponsor
- Second Affiliated Hospital of Nanchang University
Record details
- Record id
cardio:ct-nct07807384- Content hash
c50541e08915a0240edd2b85df84196ee190a8c7eebe3e9cb23549192a165bcd